Business
aTyr Pharma Presents Research Demonstrating Effects of Novel NRP2-Targeting Antibody, ATYR2810, on Tumor Associated Macrophages at the Society for Immunotherapy of Cancer Annual Meeting
Findings provide key insights into ATYR2810’s potential mechanism of action, including ability to modulate key immune cells involved in tumor progression,
About this update from Atyr Pharma, Inc.
[{"type":"text","content":" Findings provide key insights into ATYR2810’s potential mechanism of action, including ability to modulate key immune cells involved in tumor progression, metastasis and therapy resistance. Data will support the clinical development of ATYR2810, including a Phase 1 study in cancer next year. SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced a poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, which is being held November 10 – 14, 2021 in Washington, DC, and virtually. The full text of the corresponding abstract is available on the SITC website. The poster will be available for browsing on the SITC website starting Friday, November 12 at 7:00 a.m. ET through Sunday, November 14 at 5:00 p.m. ET. The poster presents preclinical findings for ATYR2810, providing key insights into its mechanism of action that will help support the clinical development of ATYR2810, including a Phase 1 study in cancer next year. ATYR2810, an anti-Neuropilin-2 (NRP2) monoclonal antibody that blocks NRP2’s VEGF-induced signaling axis, was developed from aTyr’s research platform focused on targeting human disease pathways associated with extracellular tRNA synthetases. This work details the effects of ATYR2810 on tumor associated macrophages (TAMs) differentiated from human triple-negative breast cancer tumor cells. Treatment with ATYR2810 was shown to decrease the suppressive capabilities of TAMs against T cells compared to untreated TAMs. Furthermore, TAMs treated with ATYR2810 showed a decrease in ZEB1 gene expression, which is a master transcription factor regulating epithelial-mesenchymal transition (EMT), a process that is of great importance in regulating tumor growth, progression and metastatic cascade as well as being implicated in tumor evasion of the immune system. These results suggest that ATYR2810 may be able to treat cancer by targeting tumor immune avoidance mechanisms as well as regulating EMT. Details of the poster and corresponding abstract are as follows: Title: ATYR2810, an anti-NRP2 monoclonal antibody, targets tumor associated macrophagesAuthors: Samantha Tyler, Michaela Ferrer, Erik Escobedo, Kaitlyn Rauch, Sofia Klopp-Savino, J...